Be Biopharma unveils promising preclinical results for hypophosphatasia treatment using engineered B cell medicines

Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia (HPP), a rare genetic disorder. During the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, the company showcased how BCMs, developed using CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design, successfully produced active alkaline phosphatase (ALP), which is deficient in individuals with HPP.

Key Points of the Research:

– The research focused on modifying primary human B cells to secrete ALP, an enzyme crucial for bone mineralization, using CRISPR/Cas9 and AI-based protein design.

– Engineered BCMs demonstrated the ability to produce active ALP proteins, with significant in vitro phenotypic correction in osteoblast precursor mineralization models.

– The BCM approach could offer a less invasive, redosable, and durable alternative to the existing enzyme replacement therapy, which requires multiple weekly injections and is currently approved only for pediatric-onset forms of HPP.

Innovative Approach and Potential Impact:

The BCM technology represents a significant step forward in the field of gene and cell therapy. By utilizing a safe harbor locus, CCR5, for the insertion of the ALP gene expression cassette, and optimizing protein constructs for activity and stability via an AI-based design engine, Be Biopharma is paving the way for potentially transformative treatments not only for HPP but also for a wide range of diseases.

Rick Morgan, Chief Scientific Officer at Be Biopharma, emphasized the study’s implications: “This study demonstrates how BCMs coupled with artificial intelligence-guided protein design broaden the potential of our medicines to express highly effective conjugated therapeutic proteins such as ALP-Fc fusion proteins,” he noted. He also highlighted the capability of BCMs to provide “constant and durable protein levels without preconditioning, are redosable, and can be applied to a wide range of diseases, including a potential first-in-class medicine for people living with HPP.”

Exploring the Future of BCMs:

As Be Biopharma continues to explore the capabilities of BCMs, this innovative approach could herald a new era in therapeutic biologics. The ability to engineer B cells to produce specific therapeutic proteins offers a promising platform that could be customized for various protein classes and patient populations, thereby broadening the scope of treatable conditions with cellular medicines.

The latest advancements by Be Biopharma signify a substantial leap in gene therapy technologies. By integrating AI and precise gene-editing tools, BCMs could offer more sustainable, patient-friendly treatments for genetic diseases like HPP, which currently have limited treatment options. This could greatly enhance the quality of life for patients and reduce the burden of disease management.